Jan 17, 2023 6:30am EST Viveve Announces Topline Results from Pivotal U.S. PURSUIT Trial for Treating Female Stress Urinary Incontinence
Dec 15, 2022 8:28am EST Viveve Announces Completion of Pivotal US PURSUIT Trial for Female Stress Urinary Incontinence with Final 12-month Follow-up Visits Concluded
Dec 01, 2022 8:28am EST Viveve Announces Issuance of Second U.S. Method Patent for Treating Female Stress Urinary Incontinence
Nov 10, 2022 4:02pm EST Viveve Reports Third Quarter 2022 Financial Results and Provides Corporate Update
Oct 27, 2022 8:28am EDT Viveve to Report Third Quarter 2022 Financial Results and Provide Corporate Update on November 10, 2022
Oct 04, 2022 8:28am EDT Viveve Announces Notice of Allowance for Second U.S. Method Patent for Treating Female Stress Urinary Incontinence
Sep 27, 2022 8:28am EDT Viveve Launches Rebranding Initiative to Reflect Focus on Treatment of Female Stress Urinary Incontinence in Anticipation of U.S. Pivotal PURSUIT Trial Readout
Sep 01, 2022 8:28am EDT Viveve to Participate in H.C. Wainwright 24th Annual Global Investment Conference